Add Yahoo as a preferred source to see more of our stories on Google. TUPELO — High blood pressure, or hypertension, is the top preventable cause of strokes and heart attacks in the United States, ...

Deepak L. Bhatt, MD, MPH, MBA, of Mount Sinai Fuster Heart Hospital, spoke at the recent ASPC 2025 Congress on CVD Prevention to illustrate both the benefits and risks associated with renal ...

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth interventional cardiologists treated the first patient with a revolutionary new renal denervation (RDN) procedure, now offered for patients with poorly ...

CHICAGO, IL—In the expanded SPYRAL HTN-ON MED trial, renal denervation with the Symplicity Spyral multielectrode catheter (Medtronic) failed to meet its primary endpoint in terms of blood ...

ATLANTA - At 69, Paul Griffin of Newnan has been living with high blood pressure for about 25 years. Diagnosed in his early 40s, Griffin's doctor put him on a drug that, he says, caused some negative ...

Renal denervation using radiofrequency energy is a cost-effective and high-value intervention for the treatment of uncontrolled hypertension from the perspective of the US healthcare system, an ...

Cardiologists are welcoming the arrival of a new device-based hypertension treatment called renal denervation and asking Medicare to cover the procedure for a large patient population. Doctors, ...

(RTTNews) - Medtronic plc (MDT) said that SYMPLICITY HTN-3 trial data showed sustained long-term blood pressure reductions with its renal denervation procedure. According to the company, patients who ...

Ideal BP for Kidney Disease Patients May Be 130-159/70-89 Control patients who crossover to Symplicity system also experience significant drop in BP Renal denervation seems safe and provides sustained ...

BOROUGH PARK — AN INNOVATIVE PROCEDURE TO CALM THE NERVOUS SYSTEM AND KIDNEYS was launched at Maimonides Medical Center this week. Maimonides has become the first hospital in Brooklyn to offer the ...

The US Food and Drug Administration (FDA) is expected to have data next year that could lead to approval of a renal denervation device to lower blood pressure—but will the data be strong enough to ...